SCHEMBL1673169

SCHEMBL1673169

CC(=O)N[C@H](C=O)[C@@H](O)[C@H](O)[C@@H](C)O

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.32
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29425228 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL10511364 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL30655986 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL29009630 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL524648 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL31006936 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL2510639 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL6384699 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL702670 1.00 PAX8 (0.32) PAX8ALDH1A1
SCHEMBL2693783 1.00 PAX8 (0.32) PAX8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404533-B2 Bioconjugate vaccines' synthesis in prokaryotic cell lysates NORTHWESTERN UNIVERSITY (US) 2025-09-02 US disclosed
US-12365930-B2 Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates NORTHWESTERN UNIVERSITY (US) 2025-07-22 US disclosed
US-20240277824-A1 BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-08-22 US disclosed
US-20230279460-A1 METHOD FOR RAPID IN VITRO SYNTHESIS OF GLYCOPROTEINS VIA RECOMBINANT PRODUCTION OF N-GLYCOSYLATED PROTEINS IN PROKARYOTIC CELL LYSATES NORTHWESTERN UNIVERSITY 2023-09-07 US disclosed
US-20230212633-A1 COMPOSITIONS AND METHODS FOR RAPID IN VITRO SYNTHESIS OF BIOCONJUGATE VACCINES IN VITRO VIA PRODUCTION AND N-GLYCOSYLATION OF PROTEIN CARRIERS IN DETOXIFIED PROKARYOTIC CELL LYSATES CORNELL UNIVERSITY 2023-07-06 US disclosed
CN-116171328-A Method for producing purified mixtures of different oligosaccharides produced by cell culture or microbial fermentation 因比奥斯公司 2023-05-26 CN disclosed
US-11542538-B2 Method for rapid in vitro synthesis of glycoproteins via recombinant production of n-glycosylated proteins in prokaryotic cell lysates CORNELL UNIVERSITY (US) 2023-01-03 US disclosed
US-11530432-B2 Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates NORTHWESTERN UNIVERSITY (US) 2022-12-20 US disclosed
US-20220267821-A1 BIOCONJUGATE VACCINES' SYNTHESIS IN PROKARYOTIC CELL LYSATES CORNELL UNIVERSITY 2022-08-25 US disclosed
EP-3908669-A1 BIOCONJUGATE VACCINES' SYNTHESIS IN PROKARYOTIC CELL LYSATES Northwestern University (US) 2021-11-17 EP disclosed
WO-2007035897-A2 IMPROVED LIVE ATTENUATED VACCINE STRAIN FOR PREVENTION OF TULAREMIA PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-03-29 WO disclosed
EP-1509607-A1 IMMUNOGENIC SEQUENCES The Secretary of State for Defence (GB) 2005-03-02 EP disclosed
WO-2003102191-A1 IMMUNOGENIC SEQUENCES THE SECRETARY OF STATE FOR DEFENCE (GB) 2003-12-11 WO disclosed
US-6562514-B1 Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries PINNACLE VRB LIMITED (AU) 2003-05-13 US disclosed
US-6468688-B2 CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE PINNACLE VRB LIMITED (AU) 2002-10-22 US disclosed
US-20010028977-A1 Charging, discharging efficiency; vanadium electrolyte JD HOLDING INC. (KY) 2001-10-11 US disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 US disclosed
EP-0729648-A4 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LTD (AU) 1997-01-02 EP disclosed
EP-0729648-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-09-04 EP disclosed
WO-1995012219-A1 STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1995-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240277824-A1 BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS OSTC, DDOST, NGLY1 PAX8 2301/4885ALDH1A1 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.